Nanjing Zhenhua Pharmaceutical Technology Development

Nanjing Zhenhua Pharmaceutical Technology Development Co., Ltd. is a research and development-focused pharmaceutical company based in Nanjing, China, and serves as the core R&D subsidiary of Nanjing Sanhome Pharmaceutical. Founded in 1994, the company specializes in the discovery and clinical development of small molecule drugs, particularly in the fields of oncology, anti-infectives, and cardiovascular health. It has successfully developed several significant therapies for the Chinese market, including the third-generation EGFR inhibitor Rezivertinib for lung cancer and treatments for chronic hepatitis B. The company's expertise spans the entire drug development process, from molecular design and chemical synthesis to clinical trial management and regulatory submission. By leveraging its strong technical foundation, Nanjing Zhenhua supports the broader portfolio of its parent company, which is recognized as one of China's top pharmaceutical innovators. The company continues to advance a pipeline of novel candidates aimed at addressing unmet medical needs in infectious diseases and cancer.